Acura Pharmaceuticals (ACUR) Price Target Lowered to $0.58 at S&P Equity Research

Acura Pharmaceuticals (OTCMKTS:ACUR) had its price target reduced by stock analysts at S&P Equity Research from $0.74 to $0.58 in a research note issued to investors on Wednesday. S&P Equity Research’s price objective points to a potential downside of 30.95% from the stock’s current price.

Separately, ValuEngine upgraded shares of Acura Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st.

Shares of Acura Pharmaceuticals (OTCMKTS:ACUR) traded up $0.23 during mid-day trading on Wednesday, hitting $0.84. 235,140 shares of the company traded hands, compared to its average volume of 27,733. The company has a market cap of $17.47, a P/E ratio of -5.60 and a beta of 2.05. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.44. Acura Pharmaceuticals has a 1-year low of $0.29 and a 1-year high of $1.40.

Acura Pharmaceuticals (OTCMKTS:ACUR) last issued its quarterly earnings data on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. Acura Pharmaceuticals had a negative return on equity of 231.18% and a negative net margin of 36.20%. The business had revenue of $0.08 million during the quarter.

In related news, VP Peter A. Clemens acquired 300,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was acquired at an average cost of $0.10 per share, for a total transaction of $30,000.00. Following the transaction, the vice president now directly owns 355,182 shares in the company, valued at $35,518.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Claudius Llc sold 2,195,734 shares of the company’s stock in a transaction that occurred on Friday, December 14th. The stock was sold at an average price of $0.10, for a total transaction of $219,573.40. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 1,035,734 shares of company stock valued at $103,573. 5.60% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/17/acura-pharmaceuticals-acur-price-target-lowered-to-0-58-at-sp-equity-research.html.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply